Nodal evaluation as the arbiter of oncologic equivalence: reassessing segmentectomy after CALGB 140503 and JCOG0802

Two randomized trials, CALGB 140503 and JCOG0802, established segmentectomy as an oncologically acceptable alternative to lobectomy for small, peripheral, clinically node-negative non-small cell lung cancer. Both reached that conclusion under a protocol-enforced condition that is rarely emphasized when their results are applied in practice: nodal status had to be verified intraoperatively against a defined anatomic standard. CALGB 140503 required frozen-section confirmation of N0 status at two mediastinal stations and one major hilar node before randomization, whereas JCOG0802 mandated systematic or selective dissection of N1 and N2 stations in both arms and explicitly disallowed sampling as a substitute. This review examines whether that nodal rigor is reproduced, or even reported, once segmentectomy leaves the trial setting. National data indicate that it is not. Segmentectomy accounts for 4.4% of resections for clinical stage I to IIA disease, and only 12.6% of segmentectomy cases met all three Commission on Cancer quality measures, with adherence concentrated in academic and higher-volume programs. Retrospective series consistently report lower nodal upstaging after segmentectomy than after lobectomy, but the difference is driven by N1 rather than N2 stations and tracks the smaller nodal footprint of the operation, so a lower upstaging rate cannot by itself distinguish less disease from less looking. Anatomic mapping data indicate that exhaustive intersegmental dissection is unnecessary, whereas reliable hilar and mediastinal sampling is not. Across the wider literature, adequate nodal evaluation is defined inconsistently and reported at a granularity too coarse for readers to verify compliance, a two-axis problem that we characterize here for the segmentectomy literature specifically. Robotic assistance increases the number of nodal stations harvested relative to video-assisted surgery but has not been shown to improve risk-adjusted detection of occult disease. We propose a seven-point minimum standard, anchored on station-based rather than count-based adequacy, for segmentectomy performed outside a clinical trial.